Research Finds MyoPro® Delivers Meaningful Improvements in Motor Function for Brain Injury Patient

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that new published research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “Despite long-standing traumatic brain injury, meaningful improvements in motor function were observed.”

The Case Report in the Journal of Rehabilitation and Assistive Technologies Engineering (RATE), a peer-reviewed interdisciplinary journal, studied a 42-year-old female, 29.5 years post-traumatic brain injury with diminished motor control/coordination and learned nonuse of the right arm. The research consisted of 9 weeks of in-clinic training followed by 9 weeks of at-home use. It was funded by the U.S. Department of Defense through an award to Dr. Stefania Fatone at the Northwestern University Feinberg School of Medicine in Chicago and conducted by a research team at the Louis Stokes Cleveland VA Medical Center led by Dr. Svetlana Pundik.

The report can be found here https://journals.sagepub.com/doi/full/10.1177/2055668320921067.

The study reports “During in-clinic training, active range of motion, tone, muscle power, Fugl-Meyer, box and blocks test, and Chedoke assessment score improved. During the home-use phase, decrease in tone was maintained and all other outcomes declined but were still better upon study completion than baseline.”

Lead author Svetlana Pundik, MD, MSc, Brain Plasticity and Neuro Recovery Laboratory, Louis Stokes Cleveland VA Medical Center, said “This individual had a very limited use of her arm before intervention with the device. In addition to the therapeutic benefits we measured, the patient’s caregivers reported functional improvement in her home setting. It is very heartwarming to see these improvements in a person even this many years after injury. This research is continuing now with a larger population of patients.”

Paul R. Gudonis, Myomo CEO, said “MyoPro not only extends the limited therapy time available in the clinic to continue in the home, it may also restore a person’s ability to perform activities of daily living such as feeding one’s self and performing light household tasks. As a result, users see an improved quality of life, some may return to work, and they may reduce their overall healthcare costs.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit www.myomo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including the expectations related to publication of research concerning its product, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

• our sales and commercialization efforts;

• our ability to achieve reimbursement from third-party payers for our products;

• our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;

• our ability to effectively execute our business plan and scale up our operations;

• our expectations as to our development programs; and

• general market, economic, environmental and social factors, including the ongoing COVID-19 pandemic, that may affect the evaluation, fitting, delivery and sale of our products to patients.

More information about these and other factors that potentially could affect our financial results is included in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005007/en/